PGI3 COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS
May 1, 2004, 00:00
10.1016/S1098-3015(10)62459-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)62459-X/fulltext
Title :
PGI3 COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)62459-X&doi=10.1016/S1098-3015(10)62459-X
First page :
Section Title :
Open access? :
No
Section Order :
397